ASMB (Assembly Biosciences) Debt-to-Asset : 0.01 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASMB Assembly Biosciences Inc ASMB
32 GF Score
Price $26.81
! 3 Warning Signs
View Full Analysis

What is Assembly Biosciences Debt-to-Asset?

Assembly Biosciences ASMB +3.79% 32 Debt-to-Asset is 0.01 as of Mar. 2026. GuruFocus rates ASMB with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

Assembly Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $0.59 Mil. Assembly Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $1.90 Mil. Assembly Biosciences's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2026 was $235.51 Mil. Assembly Biosciences's debt to asset for the quarter that ended in Mar. 2026 was 0.01.

Assembly Biosciences  (NAS:ASMB) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Assembly Biosciences Debt-to-Asset Related Terms

Assembly Biosciences Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Assembly Biosciences's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Assembly Biosciences Debt-to-Asset Chart

Assembly Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.03 0.02 0.03 0.01

Assembly Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.04 0.01 0.01 0.01

ASMB vs CTNM, PRTA, RGNX: Debt-to-Asset Comparison

For the Biotechnology subindustry, Assembly Biosciences's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Assembly Biosciences Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Assembly Biosciences's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Assembly Biosciences's Debt-to-Asset falls into.


ASMB
32GF Score
Assembly Biosciences Inc ASMB
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Assembly Biosciences Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Assembly Biosciences's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.569 + 2.059) / 257.59
=0.01

Assembly Biosciences's Debt-to-Asset for the quarter that ended in Mar. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.59 + 1.901) / 235.508
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.01 mean?
Assembly Biosciences (ASMB) has a Debt-to-Asset of 0.01 as of Mar. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Assembly Biosciences and its competitors.
Is Assembly Biosciences' Debt-to-Asset too high?
Assembly Biosciences' current Debt-to-Asset is 0.01. Overall, Assembly Biosciences has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Assembly Biosciences' Debt-to-Asset compare to CTNM and PRTA?
Assembly Biosciences' Debt-to-Asset of 0.01 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Assembly Biosciences and its competitors. Assembly Biosciences's current Debt-to-Asset is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Assembly Biosciences stock overvalued right now?
Assembly Biosciences (ASMB) has a current Debt-to-Asset of 0.01. The current Debt-to-Asset is 0.01. Assembly Biosciences' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Assembly Biosciences (ASMB), the current Debt-to-Asset is 0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Assembly Biosciences Business Description

Other Exchanges V7B:Germany
Address Two Tower Place, 7th Floor, South San Francisco, CA, USA, 94080
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
32GF Score

Get the complete analysis for ASMB

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.81
Price